AbbVie Inc. $ABBV Stock Sold by Capital Investment Advisors LLC

Key Points

• Capital Investment Advisors LLC reduced its AbbVie position by 4.9% in the third quarter, selling 16,536 shares and retaining 318,211 shares valued at approximately $83.2 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie received FDA approval for a more convenient subcutaneous SKYRIZI induction regimen for Crohn’s disease, supporting the drug’s growth prospects as the company moves beyond Humira. However, investors remain cautious ahead of earnings, with the stock near its 52-week high and trading at a premium valuation.
• AbbVie declared a quarterly dividend of $1.73 per share, equivalent to a $6.92 annualized payout and a 2.4% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $279.86.

Capital Investment Advisors LLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 4.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 318,211 shares of the company's stock after selling 16,536 shares during the period. AbbVie accounts for 1.0% of Capital Investment Advisors LLC's investment portfolio, making the stock its 27th largest position. Capital Investment Advisors LLC's holdings in AbbVie were worth $83,241,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC increased its holdings in AbbVie by 2.9% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 52,577 shares of the company's stock worth $13,754,000 after acquiring an additional 1,504 shares during the last quarter. BRIA Capital Group LLC raised its stake in AbbVie by 23.9% in the 3rd quarter. BRIA Capital Group LLC now owns 4,999 shares of the company's stock valued at $1,308,000 after acquiring an additional 963 shares during the period. XXI Wealth LLC raised its stake in AbbVie by 10.5% in the 3rd quarter. XXI Wealth LLC now owns 8,029 shares of the company's stock valued at $2,100,000 after acquiring an additional 762 shares during the period. BIP Wealth LLC raised its stake in AbbVie by 2.3% in the 3rd quarter. BIP Wealth LLC now owns 9,254 shares of the company's stock valued at $2,421,000 after acquiring an additional 205 shares during the period. Finally, River Street Advisors LLC lifted its holdings in AbbVie by 2.2% during the third quarter. River Street Advisors LLC now owns 14,074 shares of the company's stock valued at $3,682,000 after purchasing an additional 297 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Stock Performance

NYSE:ABBV opened at $285.66 on Friday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $291.40. The firm has a market cap of $504.70 billion, a price-to-earnings ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24. The business's fifty day moving average is $266.33 and its 200 day moving average is $241.77.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. During the same quarter in the prior year, the firm posted $2.97 EPS. The firm's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts predict that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie's dividend payout ratio is currently 195.48%.

Analyst Ratings Changes

ABBV has been the subject of a number of research reports. Wells Fargo & Company increased their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a research report on Monday, August 17th. Erste Group Bank raised shares of AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th. UBS Group upped their price target on shares of AbbVie from $260.00 to $275.00 and gave the company a "neutral" rating in a research note on Tuesday, October 6th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $280.00 price objective on shares of AbbVie in a report on Tuesday, October 13th. Finally, Morgan Stanley raised their price objective on shares of AbbVie from $296.00 to $310.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $279.86.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company's stock.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.